Photo: Unsplash

Epizyme has secured $100 million in private equity funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced Nov. 7 and financed by Royalty Pharma.” data-reactid=”22″>Cambridge-based biopharma company Epizyme has secured $100 million in private equity funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced Nov. 7 and financed by Royalty Pharma.

According to its Crunchbase profile, “Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.”

The 13-year-old company has raised five previous funding rounds, including a $10 million post IPO equity round in 2014.

The round brings total funding raised by Cambridge companies in health care over the past month to $391 million, an increase of $181 million from the month before. The local health care industry has seen 91 funding rounds over the past year, capturing a total of $3.4 billion in venture funding.

EGenesis announced a $100 million Series B funding round on Nov. 7, led by Fresenius Medical Care.” data-reactid=”26″>In other local funding news, biopharma company EGenesis announced a $100 million Series B funding round on Nov. 7, led by Fresenius Medical Care.

According to Crunchbase, “EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage.”

Founded in 2014, the company has raised two previous rounds, including a $38 million Series A round in 2017.

Click here for more about what we’re doing. Got thoughts? Go here to share your feedback.” data-reactid=”29″>This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we’re doing. Got thoughts? Go here to share your feedback.

Source